Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Emphysema Market Valuation Change Between Now And 2029?

In the past few years, the market size for emphysema has shown a consistent growth trend. It is projected to expand from $4.74 billion in 2024 to $4.94 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.3%. The historical growth of this market is largely due to the rise in respiratory diseases, an aging population, the surge in smoking rates, escalating air pollution levels, growing government endeavors, and more individuals engaging in tobacco smoking.

In the coming years, a consistent growth is predicted for the Emphysema market, which is expected to reach $5.91 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 4.6%. The expansion during the projected period can be associated with factors such as increased health care expenditure, escalating environmental pollution, growing demand for diagnostic medical aid, increasing vehicular traffic, and an escalated need for minimal invasive procedures. The forecast period will also witness dominant trends like novel inhalation devices, strategic collaborations, personalized medication, telemedicine, progression in inhalation therapies, and medical advancements.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp

What Underlying Factors Are Supporting The Emphysema Market Growth?

The emphysema market is predicted to expand in light of the escalating occurrence of respiratory infections. These infections impact the respiratory system, encompassing the sinuses, throat, airways, and lungs. Pollution, climate change, antimicrobial resistance, urbanization, and mutating pathogens contribute to the proliferation of respiratory infections. Such infections expedite the progression of emphysema by inducing inflammation, tissue injury, and heightened airway obstruction, further deteriorating lung function. As evidence, the Centers for Disease Control and Prevention, a government agency in the U.S., reported in November 2024 that in 2023, there were 9,633 instances of tuberculosis (TB) in the U.S., marking a 15.6% increase from 8,332 cases in 2022. The incidence rate also climbed from 2.5 to 2.9 per 100,000 individuals, a rise of 15.0%. Hence, the mounting prevalence of respiratory infections is fueling the growth of the emphysema market.

Which Sub-Segments Are Driving Growth Within The Emphysema Market?

The emphysemamarket covered in this report is segmented –

1) By Type: Centrilobular; Panlobular

2) By Treatment: Medication; Therapy; Surgery; Other Treatments

3) By Diagnosis: Imaging Test; Lung Function Test; Other Diagnosis

4) By Complications: Chest Infections; Collapsed Lung; Heart Problems; Lungs Hole; Other Complications

5) By End-user: Hospitals And Clinics; Surgical Center; Other End-users

Subsegments:

1) By Centrilobular: Mild Centrilobular Emphysema; Moderate Centrilobular Emphysema; Severe Centrilobular Emphysema

2) By Panlobular: Mild Panlobular Emphysema; Moderate Panlobular Emphysema; Severe Panlobular Emphysema

What Key Trends Are Driving Growth In The Emphysema Market?

In the emphysema market, leading companies are developing innovative therapies such as inhaled dual inhibitors of phosphodiesterase 3 and 4 to offer improved treatments that enhance lung function, reduce inflammation, and better manage the disease, thus improving respiratory health and quality of life. These inhaled dual inhibitors target and block both PDE3 and PDE4 enzymes in the lungs, helping to relax airways and decrease inflammation in diseases like chronic obstructive pulmonary disease. For instance, in June 2024, UK-based Verona Pharma plc launched Ohtuvayre (ensifentrine), the first inhaled dual PDE3 and PDE4 inhibitor approved by the FDA for maintenance treatment of COPD including emphysema, marking the first new inhaled therapy in over two decades. The drug, which combines bronchodilator and anti-inflammatory effects, will be distributed via specialty pharmacies.

Which Companies Hold A Competitive Edge In The 1541 Market?

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., Olympus Corporation, ResMed Inc., Chiesi Farmaceutici S.p.A., University of Chicago Medicine (UChicago Medicine), Hikma Pharmaceuticals PLC, United Therapeutics Corporation, VIDA Diagnostics Inc., Kamada Limited, Pulmonx Corporation, Mereo BioPharma Group PLC, Uptake Medical Corporation, Verona Pharma PLC.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Which Region Dominates The Emphysema Market Today?

North America was the largest region in the emphysema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp

Browse Through More Reports Similar to the Global Emphysema Market 2025, By The Business Research Company

Emphysema Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

Lung Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Lung Cancer Diagnostic And Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model